Relmada Therapeutics names Jørn Skibsted Jakobsen chief development officer for urology and uro-oncology
RLMD•Relmada Therapeutics appointed Jørn Skibsted Jakobsen chief development officer for urology and uro-oncology. He will lead clinical development across the pipeline, including the planned Phase 3 SPECTRUM program for NDV-01.
1. Development leadership
Jakobsen will lead clinical development across Relmada’s pipeline, including the planned Phase 3 SPECTRUM program for NDV-01. He is a board-certified urologist and led ADSTILADRIN’s pivotal clinical development program during nine years at Ferring Pharmaceuticals.




